SCHEMBL6465724

SCHEMBL6465724

COc1cc(OC)c2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(OCCNC(C)CO)ccc4n3)nc(C)c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.34
ALDH1A1 P00352 5/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
USP2 O75604 2/20 0.33
TDP2 O95551 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 8/20 0.33
TDP1 Q9NUW8 2/20 0.33
HTT P42858 2/20 0.33
PSMD14 O00487 1/20 0.33
APAF1 O14727 1/20 0.33
MITF O75030 1/20 0.33
HPGD P15428 1/20 0.33
PTK2B Q14289 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
TSHR P16473 1/20 0.32
GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469046 0.90 MAPT (0.36) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6467386 0.90 TDP2 (0.36) MAPTALDH1A1HSD17B10MEN1KMT2A
Trifluoroacetic Acid SCHEMBL6465715 0.88 ALDH1A1 (0.35) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6470081 0.88 NPSR1 (0.37) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6469705 0.85 ALDH1A1 (0.33) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6470898 0.85 MEN1 (0.36) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL6467480 0.84 TLR7 (0.34) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL6470906 0.84 HRH3 (0.39)
SCHEMBL6469115 0.84 MAPT (0.35) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6465747 0.83 MAPT (0.36) MAPTALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB MAPT 3552/4885ALDH1A1 3154/4885HSD17B10 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.